Safety Issue Halts Study of BMS HCV Drug
(MedPage Today) — Bristol-Myers Squibb has suspended treatment “to protect patient safety” in a phase IIb trial of an investigational oral drug for hepatitis C.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com